CIK 0001626971
- Non-accelerated filer
- Smaller reporting company
Corvus Pharmaceuticals, Inc.
Sign in to watch- Ticker
- CRVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464670809
- Phone
- +1 650-900-4520
- Business address
- 901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Open-market buy President and CEO bought 5,890 shares at an average $0.98 ($5,797)
- 4 Open-market buy President and CEO bought 15,000 shares at $1.64 ($24,534)
- 4 Open-market buy Chief Financial Officer bought 49,038 shares at an average $1.57 ($77,045)
- 4 Open-market buy President and CEO bought 30,000 shares at an average $1.49 ($44,600)
- 4 Open-market sale 10% owner sold 5,000,000 shares at an average $5.01 ($25,059,900)
- 4 Open-market sale Director sold 1,109,644 shares at $6.09 ($6,757,732)
- 4 Open-market sale Director sold 1,109,644 shares at $6.09 ($6,757,732)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy President and CEO bought 10,000 shares at $1.93 ($19,254)
Page 5 of 13 · 252 filings